BSD Medical's Innovative Technology Could Spare 'the Majority' Of Limb Cancer Patients From Amputation
MUNICH, Germany, Aug. 12 /PRNewswire-FirstCall/ -- BSD Medical Corp. (BULLETIN BOARD: BSDM) today announced that a team of researchers in Munich has applied BSD's technology in an innovative therapy that could allow the majority of cancer victims facing limb amputation to keep their arms and legs.
The clinical trial behind the report showed that with the new therapy, there was no reduction in 5-year survival when patients avoided amputation.
The innovative feature of the therapy, according to the report delivered at the American Society of Clinical Oncology conference in Chicago (ASCO 2003), is the combination of regional hyperthermia and chemotherapy for initial treatment of high-risk, soft tissue sarcomas in the limbs.
Surgery, radiation and postoperative chemotherapy are then performed according to conventional methods. Limb preservation was achieved in 37 of 47 patients treated with the new therapy (79% preservation success), even though these patients were from a population where amputation would normally have been recommended.
Authors of this report are Drs. M. Schlemmer (lead author), C. M. Wendtner, L. Linder, S. Abdel-Rahman, W. Hiddemann and R. D. Issels. The authors are representatives from Ludwig-Maximilians University, GSF-National Research Center for Environmental Health, and the Institute of Molecular Immunology, all of Munich, Germany.
Hyperthermia therapy heats cancer to fever-level temperatures. It is used to improve the performance of chemotherapy because chemotherapy drugs become more potent at higher temperatures, and because heat increases the blood flow carrying the drug into the cancer.
Many clinical trials have shown significantly better results when hyperthermia was added to chemotherapy.
In this study, the objective was to give the patient a powerful head start against the cancer by adding an initial treatment with the combination of hyperthermia and chemotherapy.
The BSD-2000 hyperthermia system by BSD Medical was used for this study. BSD Medical Corp. (BSDM) is the leading developer of hyperthermia systems for treating cancer. BSD's hyperthermia systems provide precisely focused microwave energy that heats cancerous tissue to exact temperatures.
Hyperthermia is used to boost the effectiveness of radiation, as well as chemotherapy, in treating cancer. To learn more about BSD Medical and hyperthermia therapy, visit www.bsdmc.com .
Statements contained in this press release that are not historical facts are forward looking statements, as that item is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties (detailed in the Company's filings with the Securities and Exchange Commission) that could cause actual results to differ materially from estimated results.
Source: BSD Medical Corp.
CONTACT: Hyrum A. Mead of BSD Medical Corp., +1-801-972-5555, or fax,
Web site: http://www.bsdmc.com/
Intl J Hyperthermia, 3/03
J Clin Onc, 12/03
J Clin Oncol, 12/03
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.